Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DGQQ | ISIN: US5526411021 | Ticker-Symbol:
NASDAQ
30.10.24
19:27 Uhr
2,820 US-Dollar
+0,055
+1,99 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MAIA BIOTECHNOLOGY INC Chart 1 Jahr
5-Tage-Chart
MAIA BIOTECHNOLOGY INC 5-Tage-Chart

Aktuelle News zur MAIA BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMAIA Biotechnology prices $2.44M private placement2
15.10.MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics149MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical...
► Artikel lesen
10.09.MAIA Biotechnology, Inc. - 8-K, Current Report1
09.08.MAIA Biotechnology, Inc. - 10-Q, Quarterly Report1
23.07.MAIA Biotechnology, Inc. - 8-K, Current Report1
23.07.MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients1
23.07.MAIA Biotech Reports Positive Phase 2 Data For THIO With Cemiplimab In Non-Small Cell Lung Cancer1
06.06.MAIA Biotechnology, Inc. - 8-K, Current Report-
04.06.MAIA Biotech's Phase 2 THIO-101 Study Shows Positive Results In Non-Small Cell Lung Cancer4
29.05.MAIA Biotechnology, Inc. - 8-K, Current Report2
15.05.MAIA Biotechnology, Inc. - 8-K, Current Report2
14.05.MAIA Biotechnology, Inc. - 10-Q, Quarterly Report1
07.05.MAIA Biotechnology, Inc. - 8-K, Current Report1
22.02.MAIA Biotechnology, Inc.: MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer529Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb....
► Artikel lesen
17.11.23MAIA Biotechnology Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer408CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., with...
► Artikel lesen
07.11.23MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO201CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1